Skip to content
DataLookout
Menu

ESTIMATIONNCT07789574

Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment reopened Show 4 more changesShow less
    • Lead sponsor: Thomas Ernst, PD Dr. med. to Thomas Ernst, Prof. Dr. med.
    • Start date: Jun 22, 2026 to Nov 2026
    • Eligibility criteria expanded, about 30 words
    • Trial sites expanded: 1 → 10 locations
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Rate of MR2 at 12 months
Timeframe: 12 months after start of therapy

Arms and interventions

asciminib 200 mg BIDExperimental

All patients will be treated with asciminib 200 mg BID

Drugs: asciminib 200 mg BID

Sites

10 sites in 1 country